Generic and biosimilar semaglutide: what's actually in the pipeline As of April 2026, the FDA has received zero Abbreviated New Drug Applications (ANDAs) for generic semaglutide
One of the biggest concerns I see is that people lose weight, but they also risk losing muscle, under-fueling, and feeling worse if they do not have a plan
But Part D IS required to cover GLP-1s when prescribed for medical conditions like diabetes, sleep apnea, or liver disease
On the policy side, the Medicare GLP-1 Bridge program took effect July 1, lowering copays for eligible Part D beneficiaries to $50 per month through 2027 a structural tailwind for the entire obesity treatment category
self-pay options available straightforward online process with provider messaging refills and renewals managed digitally Cons not available in all states consultation fee may apply and isnt always covered by insurance no in-person skin exam required, so some conditions may be missed mixed customer service reviews, including delays and billing issues limited to certain skin conditions
Tell patients to report development of blisters or erosions while receiving JANUMET